Journal of Multiple Sclerosis
ISSN - 2376-0389NLM - 101654564
Articles published in Journal of Multiple Sclerosis have been cited by esteemed scholars and scientists all around the world. Journal of Multiple Sclerosis has got h-index 11, which means every article in Journal of Multiple Sclerosis has got 11 average citations.
Following are the list of articles that have cited the articles published in Journal of Multiple Sclerosis.
Journal of Multiple Sclerosis has got h-index 11, which means every article in Journal of Multiple Sclerosis has got 11 average citations.Following are the list of articles that have cited the articles published in Journal of Multiple Sclerosis.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Total published articles |
50 | 59 | 6 | 3 | 9 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
54 | 59 | 46 | 57 | 43 |
| Journal total citations count | 521 |
| Journal impact factor | 2.30 |
| Journal 5 years impact factor | 2.28 |
| Journal cite score | 1.96 |
| Journal h-index | 11 |
| Journal h-index since 2019 | 9 |
| Journal Impact Factor 2020 formula |
| IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
| Journal 5-year Impact Factor 2020 formula |
| Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
| Journal CiteScore |
| CiteScorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
Claes, N., Fraussen, J., Stinissen, P., Hupperts, R., & Somers, V. (2015). B cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions. Frontiers in immunology, 6, 642. |
|
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018). Multiple sclerosis: mechanisms and immunotherapy. Neuron, 97(4), 742-768. |
|
Sánchez Morales, C. (2017). Alteraciones motoras, cognitivas y emocionales en la encefalomielitis autoinmune experimental. |
|
Ludwig, M. D. (2017). Opioid Growth Factor as a Candidate Biomarker for Multiple Sclerosis. The Pennsylvania State University. |
|
Ludwig, M. D., Turel, A. P., Zagon, I. S., & McLaughlin, P. J. (2015). Treatment of clinically isolated syndrome and low dose naltrexone. Clin Case Reports Rev, 1, 182ó184. |
|
Zagon, I. S., & McLaughlin, P. J. (2018). Intermittent blockade of OGFr and treatment of autoimmune disorders. Experimental Biology and Medicine, 243(17-18), 1323-1330. |
|
Zagon, I. S., & McLaughlin, P. J. (2017). Endogenous opioids in the Etiology and Treatment of Multiple Sclerosis. Exon Publications, Pages125-138. |
|
Ludwig, M. D., Zagon, I. S., & McLaughlin, P. J. (2018). Featured Article: Modulation of the OGF–OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis. Experimental Biology and Medicine, 243(4), 361-369. |
|
Ludwig, M. D., Zagon, I. S., & McLaughlin, P. J. (2017). Elevated serum [Met5]-enkephalin levels correlate with improved clinical and behavioral outcomes in experimental autoimmune encephalomyelitis. Brain research bulletin, 134, 1-9. |
|
Ludwig, M. D., Turel, A. P., Zagon, I. S., & McLaughlin, P. J. (2016). Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Multiple Sclerosis Journal–Experimental, Translational and Clinical, 2, 2055217316672242. |
|
Ludwig, M. D., Turel, A. P., Zagon, I. S., & McLaughlin, P. J. (2016). Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Multiple Sclerosis Journal–Experimental, Translational and Clinical, 2, 2055217316672242. |
|
Ludwig, M. D., Zagon, I. S., & McLaughlin, P. J. (2017). Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone. Experimental Biology and Medicine, 242(15), 1524-1533. |
|
McLaughlin, P. J., & Zagon, I. S. (2015). Duration of opioid receptor blockade determines biotherapeutic response. Biochemical pharmacology, 97(3), 236-246. |
|
?engül, H. S., ?engül, Y., Yücel, S., & Forta, H. (2016). Genç Multipl Skleroz ve Esansiyel Tremor Hastalar?nda Kognitif Bozulma: Kar??la?t?rmal? Bir Çal??ma. Turk J Neurol, 22, 109-113. |
|
Serdar ?engül, H., ?engül, Y., Yücel, S., & Forta, H. (2016). Cognitive Impairment in Young Multiple Sclerosis and Essential Tremor Patients: A Comparative Study. Turkish Journal of Neurology/Turk Noroloji Dergisi, 22(3). |
|
Trufanov, A., Bisaga, G., Skulyabin, D., Temniy, A., Poplyak, M., Chakchir, O., ... & Odinak, M. (2021). Thalamic nuclei degeneration in multiple sclerosis. Journal of Clinical Neuroscience. |
|
Hemrungrojn, S., Tangwongchai, S., Charoenboon, T., Panasawat, M., Supasitthumrong, T., Chaipresertsud, P., ... & Maes, M. (2021). Use of the Montreal Cognitive Assessment Thai Version to Discriminate Amnestic Mild Cognitive Impairment from Alzheimer’s Disease and Healthy Controls: Machine Learning Results. Dementia and geriatric cognitive disorders, 50(2), 183-194. |
|
Ben-Zacharia, A. B. (2020). The Association Between Body Mass Index, Brain Volume and Cognitive Function in Adult Patients with Relapsing-Remitting Multiple Sclerosis (Doctoral dissertation, New York University). |
|
Fayomy, E., Mohamed, N., Mohamed, H. H., Kamal, M. M., Alsayyad, A. H., Alsayyad, E. H., & Shamloul, R. M. (2021). Signs of neuroinflammation outweigh neurodegeneration as predictors for early conversion to MS. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 57(1), 1-6. |
|
Eskut, N., Koc, A. M., Köskderelioglu, A., Unsal Bilgin, Y. O., & Tekindal, M. A. (2021). Is there a relationship between fall status, cognition and cerebellar lobule volume in patients with multiple sclerosis?. Applied Neuropsychology: Adult, 1-11. |
|
